This lack of evidence for improvement in survival with any chemotherapy regimen has created a tabula rasa where no more large randomized trials should be conducted without including a genetic analysis.
It will take one or more large, randomized trials comparing long-term changes in memory and thinking skills among people undergoing bypass surgery, those with heart disease but no surgery, and those without heart disease to tease out how much of this can be attributed to bypass surgery, heart disease, and aging.
A recent FDA Federal Drug Administrationn) review suggested that more large randomized studies with active comparators should be conducted by the manufacturers.
However, before more differentiated exercise prescription guidelines can be used as clinical treatment guidelines, its medium to long-term efficacy should first be evaluated in more large-scale randomized controlled clinical trials.
Our results provide a foundation for future research in this area, which we recommend as including more rigorously designed, large, randomized studies.
More recently, a large randomized trial concluded that infants receiving higher protein content in infant formula during the first year of life exhibited a greater growth [5].
More recently, a large randomized, double-blind, phase 2 gene transfer clinical trial was conducted in 74 HIV-1-infected adults who received a tat-vpr-specific anti-HIV ribozyme (OZ1) or placebo delivered in autologous CD34+ hematopoietic progenitor cells.
This suggests that more high-quality, large, randomized, and double-blinded studies are necessary to secure data on this issue.
More recently, a large randomized controlled trial of patients recruited on ICU admission used additional fluid therapy and dobutamine in response to a low pHi, and failed to demonstrate any outcome difference between control and protocol groups [ 173].
More recently, two large randomized controlled trials, the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial [ 25] and the Breast International Group BIGG) 1-98 trial [ 26], evaluated the impact of CYP2D6 polymorphisms in patients treated with tamoxifen.
However, more recently, two large randomized controlled trials have shown that there is no advantage to high intensity CRRT (>35 mL/kg/h) with regard to hospital mortality [ 7, 9].
